Merlintrader’s Daily Briefing

Sunday, July 26, 2026 — the week ahead in one line: a Federal Reserve decision on Wednesday, four of the largest technology companies reporting, and the advance second-quarter GDP print and June inflation deflator to follow. The weekend added two things markets did not have on Friday. Ukraine said it struck Iran-linked cargo vessels in the Caspian Sea, tying two conflicts that had so far been separate, and LSEG’s Lipper unit disclosed that Friday’s record investment-grade bond outflow was distorted by a single transaction — without it the same week shows inflows. Equities go into Monday after a losing week for all three benchmarks, with the Nasdaq Composite down about 2.1%, the S&P 500 off 0.6% and the Dow 0.4% lower, and with the cost of the artificial-intelligence buildout, not demand for it, as the argument the market is having.

Weekend: the war reaches the Caspian
  • Ukraine strikes — President Volodymyr Zelensky said on Saturday that long-range strikes in the Caspian Sea hit vessels involved in transporting military cargo from Iran, as well as a warship. The Caspian lies more than 1,000 kilometres from Ukrainian-controlled territory.Geopolitics
  • Tehran responds — Iran’s foreign ministry said an Iranian commercial vessel was struck early on Saturday, killing one crew member and wounding another, and called the attack an act of aggression that could widen the war.Geopolitics
  • Why it is new — Until now the Ukraine and Iran theatres had been financially linked but militarily separate. A direct Ukrainian strike on Iran-linked shipping ties the two conflicts together and adds a second source of supply risk to the same barrel of oil.Geopolitics
  • The U.S. track — U.S. Central Command announced no new strikes on Iran for a second day, leaving the proposed ten-day ceasefire on the table without either side confirming a return to negotiations.Geopolitics
Trade: two fronts open at once
  • Beijing retaliates — China’s commerce ministry issued Announcement No. 30 of 2026 on Friday, adding 14 European entities to its export control list with immediate effect. Exports of Chinese dual-use items, including some rare earth elements, to those firms are prohibited.Trade
  • Who is on the list — The named entities include the German defence group Rheinmetall, Polish sensor maker Vigo Photonics, Czech truck maker Tatra, Italian motor manufacturer Lafert and French drone builder Cavok UAS — a list weighted towards European defence supply chains.Trade
  • The trigger — The move answers the European Union’s twenty-first sanctions package against Russia, adopted on 23 July, which listed 14 companies based in mainland China and Hong Kong.Trade
  • Washington and Brussels — The administration said it will open a Section 301 investigation into European Union trade practices over fines levied on American technology companies, after Brussels imposed a 2.95 billion euro antitrust penalty on Google’s ad tech business and a separate 890 million euro fine.Trade
  • Pharma timetable — The generic drug tariff plan announced last week sets a two-year transition beginning 1 August at a zero rate, followed by 100% and then 200% duties under Section 232. Most generics sold in the United States are made in Europe and India.Health Policy
The bond outflow that was not
  • The headline — Lipper data published on Friday showed U.S. investment-grade bond funds shedding $7.1 billion in the week to 22 July, the largest weekly withdrawal on record, following a record single-day outflow of $8.2 billion on 20 July.Credit
  • The correction — LSEG’s Lipper unit said on Saturday it is reviewing an unusually large transaction in one investment-grade fund that distorted the wider fixed-income flow data, after JPMorgan flagged a potential error. The fund has been removed from the current weekly report.Credit
  • What the data shows without it — Excluding the fund under review, U.S. investment-grade funds recorded net inflows of $1.54 billion over the same week — the opposite sign to the headline that circulated on Friday.Credit
AI: the financing question moves to centre stage
  • The Moody’s numbers — The rating agency put combined 2026 capital spending by Alphabet, Amazon, CoreWeave, Meta, Microsoft and Oracle at roughly $785 billion, rising towards $1 trillion by 2027, with direct debt across the group near $460 billion.AI
  • The off-balance-sheet layer — Data centre lease commitments not carried as debt were put at about $1.2 trillion, the part of the buildout least visible in headline leverage ratios. Moody’s still describes the four largest names as holding among the strongest corporate balance sheets in the world.AI
  • Debt markets are already funding it — BlackRock began marketing a $12.3 billion bond sale tied to a Meta data centre last week, one of the larger single financings of the cycle and a marker of how much of the buildout is moving off corporate balance sheets.Credit
  • The number that started it — Alphabet lifted 2026 capital expenditure guidance to $195-205 billion from $180-190 billion on 22 July, with second-quarter capex of $44.9 billion, cloud revenue up 82% to $24.8 billion and backlog at $514 billion. The shares fell despite the revenue beat.AI
Nuclear and the power bill behind AI
  • Oklo clears the gate — The Department of Energy granted startup authorisation for Oklo’s Groves isotope test reactor on 23 July under its Reactor Pilot Program, allowing fuel loading, startup testing and the approach to first criticality. The company took just over ten months from groundbreaking.Nuclear
  • Why it counts — Groves is a low-power test unit rather than a commercial plant. Its value is procedural: it establishes the operating record the company needs before larger isotope and power projects can be authorised.Nuclear
  • Demand side — Heat across the central United States is lifting power demand into the new week while the east stays cool, an increasingly relevant variable now that data centre load is competing with weather-driven consumption on the same grids.Energy
Space complex into Monday
  • Flight 13 outcome — The booster completed an on-target but hard splashdown off the Texas Gulf Coast while the upper stage flew a successful sub-orbital arc to the Indian Ocean, carrying the first 20 V3 Starlink satellites. The launch came after the close, so the equity reaction is still ahead.Space
  • The valuation setup — SpaceX shares ended Friday around $112.59, roughly 17% below the $135 June listing price and about a quarter below their debut level, after a run of consecutive declines and an aborted test on 16 July.Space
  • The read-across — The company has stopped taking new Falcon 9 rideshare reservations and is turning away dedicated bookings beyond 2028. That capacity squeeze is the mechanism through which the leader’s troubles have been dragging on $ASTS, $RKLB and $LUNR rather than lifting them.Space
Biotech: a dense regulatory week
  • Capricor — The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee reviews the deramiocel biologics licence application in Duchenne muscular dystrophy on Wednesday, from 10:00 a.m. to 4:30 p.m. Eastern. The PDUFA target action date is 22 August.Biotech
  • Replimune — A separate advisory committee on Thursday takes up RP1 with nivolumab in advanced melanoma after anti-PD-1 therapy, with a resubmission goal date of 2 August. The gap between panel and decision is unusually short.Biotech
  • Viatris — Thursday also carries the target action date for the 505(b)(2) application covering a low-dose estrogen combined hormonal contraceptive weekly patch, supported by the Phase 3 Luminous study.Biotech
  • Further out — Moderna’s seasonal influenza vaccine candidate for adults aged 50 and over has a 5 August action date, making the first week of August a continuation rather than a pause.Biotech
The Fed and the calendar
  • Wednesday — The rate decision lands at 2:00 p.m. Eastern, with Chair Kevin Warsh’s press conference half an hour later. Microsoft, Meta, Arm and Qualcomm report the same day.Rates
  • What is priced — Futures-implied odds of a quarter-point increase rose to roughly 38% by late in the week from about 11% on 15 July, driven by the oil move. A half-point step carries effectively no probability, and most surveyed economists still expect a hold in the 3.50%-3.75% range.Rates
  • The guidance vacuum — Part of the widening in those odds reflects the absence of forward guidance, which the chair discontinued on taking office in May. Less signalling means more of the uncertainty shows up as a risk premium in the futures curve.Rates
  • Monday and Tuesday — June durable goods orders open the week, followed by the S&P Case-Shiller home price index and Conference Board consumer confidence on Tuesday as the two-day meeting begins.Macro
  • Thursday — The advance reading of second-quarter GDP arrives with weekly jobless claims, the Bank of England decides, and Apple and Amazon report after the close.Macro
  • Friday — The June personal consumption expenditures price index and the second-quarter employment cost index close the week, alongside the Bank of Japan decision, euro-area inflation and results from Exxon Mobil and Chevron.Macro
  • Earnings backdrop — With more than 80 S&P 500 members reported, second-quarter earnings growth was tracking near 26.5% against a year earlier, a high bar that has so far produced beats without sustained share price reward.Earnings
Read the full Daily Briefing

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: July 15 → September 30, 2026. Compact homepage board for FDA decisions, advisory committees, regulatory submissions and major clinical readouts. October and later events are excluded from this widget.

37Active
19FDA / Reg
18Data / Filing
Jul 24Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$CAPRderamiocel panelJul 29AdCom Panel before Aug PDUFA

Capricor. FDA advisory committee for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Panel tone and briefing documents are the key pre-PDUFA read-through.

$VTRSMR-100A-01Jul 30PDUFA Low-dose estrogen weekly contraceptive patch

Viatris. FDA target action date for the 505(b)(2) NDA for the investigational low-dose estrogen combined hormonal contraceptive weekly patch. Supported by the Phase 3 Luminous study, NCT05139121.

$REPLRP1 panelJul 30AdCom Melanoma panel review

Replimune. FDA advisory committee for RP1 plus nivolumab in advanced melanoma after anti-PD-1 therapy. Single-arm evidence risk remains central.

$REPLRP1Aug 2PDUFA Melanoma BLA resubmission

Replimune. BLA resubmission goal date for RP1. This is a very compressed AdCom-to-PDUFA setup with elevated regulatory risk.

$MRNAmFLUSIVAAug 5PDUFA mRNA seasonal flu

Moderna. BLA PDUFA for mRNA seasonal flu vaccine candidate in adults 50+. More platform and lifecycle read-through than pure small-cap binary.

$REGNgaretosmabAugFDA FOP ultra-rare disease

Regeneron. BLA target action month for garetosmab in adult fibrodysplasia ossificans progressiva. Month-only calendar item.

$LNTHMK-6240Aug 13NDA Tau PET imaging

Lantheus. NDA PDUFA for MK-6240 tau PET imaging in Alzheimer’s disease. Diagnostic/imaging catalyst, not a therapeutic efficacy binary.

$CAPRderamiocelAug 22PDUFA DMD cardiomyopathy

Capricor. BLA PDUFA for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Prior CRL history and July AdCom make this highly binary.

$RAREDTX401Aug 23BLA GSDIa gene therapy

Ultragenyx. Priority Review BLA PDUFA for DTX401 in glycogen storage disease type Ia. First of two near-term Ultragenyx gene-therapy decisions.

$BIIBLeqembi IQLIKAug 24sBLA SC starting dose

Biogen / Eisai. sBLA PDUFA for once-weekly subcutaneous Leqembi starting-dose use. Large-cap Alzheimer’s lifecycle catalyst.

$JAZZZiihera comboAug 25sBLA 1L HER2+ GEA

Jazz Pharmaceuticals. sBLA PDUFA for Ziihera combination use in first-line HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDA Once-daily HIV regimen

Gilead. NDA PDUFA for bictegravir/lenacapavir in virologically suppressed adults. Strategic HIV franchise catalyst.

$PTGXrusfertideQ3PDUFA Polycythemia vera

Protagonist / Takeda. Priority Review NDA window for rusfertide in polycythemia vera. Exact date not pinned in this compact board.

$NUVLzidesamtinibSep 18NDA ROS1+ NSCLC

Nuvalent. NDA PDUFA for zidesamtinib in ROS1-positive non-small-cell lung cancer. Important targeted-oncology regulatory event.

$RAREUX111Sep 19Risk Sanfilippo A gene therapy

Ultragenyx. Resubmitted BLA PDUFA for UX111 in Sanfilippo syndrome type A. CMC and facility risk remain the key swing factors.

$IONSzilganersenSep 22NDA Alexander disease

Ionis. NDA PDUFA for zilganersen in Alexander disease. Rare neurological disease Priority Review event.

$BFRIAmeluz PDTSep 28sNDA Superficial BCC expansion

Biofrontera. PDUFA for Ameluz photodynamic therapy sNDA seeking expansion into superficial basal cell carcinoma. Small-cap liquidity can amplify reaction.

$SRRKapitegromabSep 30BLA Spinal muscular atrophy

Scholar Rock. BLA PDUFA for apitegromab in spinal muscular atrophy. Manufacturing and fill-finish facility status remain key watch items.

$ROIVbrepocitinibQ3NDA Dermatomyositis

Priovant / Roivant. NDA Priority Review window for brepocitinib in dermatomyositis. Company has pointed to potential launch timing by end-September if approved.

$QUREAMT-130Q3BLA Huntington’s AA path

uniQure. Planned BLA submission for AMT-130 in Huntington’s disease. Not a PDUFA, but one of the most important regulatory-pathway events in the quarter.

$SLNdivesiranAugData SANRECO Phase 2 PV

Silence Therapeutics. SANRECO Phase 2 topline data for divesiran in polycythemia vera. Important read-through alongside $PTGX / Takeda rusfertide.

$IMMXNXC-201Q3Data AL amyloidosis

Immix Biopharma. NEXICART-2 topline data for NXC-201 in relapsed/refractory AL amyloidosis. BLA-enabling study, high-volatility small-cap setup.

$KPTIselinexorNearData Endometrial cancer Ph3

Karyopharm. XPORT-EC-042 Phase 3 topline data for selinexor in endometrial cancer. Treat as near-term until released or formally delayed.

$KODDAYBREAKQ3Data Wet AMD Phase 3

Kodiak Sciences. DAYBREAK Phase 3 topline data for tarcocimab / KSI-501 in wet AMD. Watch efficacy, durability, dosing interval and safety.

$ALMSenvudeucitinibQ3Data SLE Phase 2b

Alumis. LUMUS Phase 2b readout for envudeucitinib in systemic lupus erythematosus. Autoimmune data can be noisy; dose response matters.

$IVVDVYD2311Q3Data DECLARATION pivotal

Invivyd. DECLARATION pivotal / Phase 3 topline data for VYD2311. COVID-antibody sentiment can be unstable, but pivotal data can still move the name.

$MPLTML-007C-MAMid-AugData ZEPHYR schizophrenia Ph2

MapLight Therapeutics. Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia. CNS readout with potentially sharp binary reaction.

$AMLXavexitideQ3Ph3 PBH pivotal LUCIDITY

Amylyx. Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia. One of the clearest Phase 3 clinical binaries of the quarter.

$PHVSdeucrictibant ERQ3Ph3 HAE prophylaxis Ph3

Pharvaris. Phase 3 CHAPTER-3 data for extended-release deucrictibant as prophylaxis for hereditary angioedema. Major HAE readout.

$SYRESPY003Q3Data IBD / UC Phase 2

Spyre Therapeutics. Phase 2 SKYLINE Part A topline data for SPY003 in inflammatory bowel disease and ulcerative colitis.

$VERATrutakna / ataciceptQ3eGFR ORIGIN 3 follow-up

Vera Therapeutics. ORIGIN 3 eGFR analysis following accelerated approval. Not another approval decision, but important for durability and confirmatory confidence.

$OCGNOCU410STQ3Data Stargardt interim analysis

Ocugen. Interim OCU410ST analysis after 24 patients complete eight months of follow-up in Stargardt disease. Small-cap ophthalmology catalyst.

$XENEazetukalnerQ3NDA Focal-onset seizures filing

Xenon. Expected NDA submission for azetukalner in focal-onset seizures. Filing confirmation would set up future FDA acceptance and PDUFA timing.

$BBIOinfigratinibQ3NDA Achondroplasia filing

BridgeBio. Expected NDA submission for infigratinib in achondroplasia. Submission timing and acceptance will define the next regulatory leg.

$CLNNCNM-Au8Q3NDA ALS accelerated pathway

Clene. Targeted NDA submission for CNM-Au8 in ALS through an accelerated pathway. Very high regulatory strategy risk because submission does not guarantee acceptance.

$OCGNOCU400Q3BLA Rolling BLA start

Ocugen. Expected start of rolling BLA submission for OCU400 in retinitis pigmentosa. Filing progress, manufacturing and future acceptance are the next watch items.

$MLTXsonelokimabLate SepBLA HS filing watch

MoonLake. Planned BLA submission for sonelokimab in hidradenitis suppurativa around the end of September. Acceptance would create the next formal FDA calendar item.

Most attention-worthy watchlist

$REPL$CAPR$RARE$NUVL$IONS$SRRK$AMLX$PHVS$QURE$MPLT

Board rule

Only July–September catalysts are shown. October and later events are intentionally excluded from this compact homepage widget. Resolved decisions are removed from the active board: $CELC Revtorpyk / gedatolisib was approved by the FDA on July 14, ahead of its July 17 PDUFA date, with the U.S. commercial launch expected in Q3 2026; $SNY Sarclisa SC was approved on July 10, ahead of its original July 23 target date. Events with only Q3 guidance are included, but should be rechecked against company filings before trading around them.

Educational content only — not investment advice. Verify dates and filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with CONSOB (Italy) and SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.

Avvertenza. Questo contenuto ha finalità esclusivamente didattiche e informative. Non costituisce consulenza finanziaria né una raccomandazione di acquisto o vendita di alcun titolo, in linea con le indicazioni CONSOB (Italia) e SEC (USA). I dati sono generati dall'AI a partire da fonti web e possono contenere errori o non essere aggiornati — verifica sempre rispetto alla fonte primaria collegata. Fai le tue ricerche e consulta un consulente autorizzato. Disclaimer completo: merlintrader.com/disclaimer.